What the Study Found (In Plain English)
Published in Contemporary clinical trials (2023), this phase iii randomized trial evaluating human clinical outcomes investigated: Randomized-controlled Phase 2 trials are routinely skipped in oncology drug development in favor of directly going to confirmatory Phase 3 after signal-detection post dose-finding in Phase 1. Key clinical takeaway: With improved standard-of-care, this speed-oriented aggressive approach is not sustainable. It is time to apply the state-of-art adaptive 2-in-1 Phase 2/3 designs to mitigate the risk of costly Phase 3 failures and allow a study to choose the optimal path to success.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Contemporary clinical trials, 2023-02-15; Phase III Randomized Trial; Rigor 82/100): With improved standard-of-care, this speed-oriented aggressive approach is not sustainable. It is time to apply the state-of-art adaptive 2-in-1 Phase 2/3 designs to mitigate the risk of costly Phase 3 failures and allow a study to choose the optimal path to success.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.